Evidence map›Paper›PMID 25291183›Full record

ArticlePloS one2014

Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet.

Rodney Rouse, Leshuai Zhang, Katherine Shea, Hongfei Zhou, Lin Xu, Sharron Stewart, Barry Rosenzweig, Jun Zhang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Adverse Effects of GLP-1 Receptor Agonists.The review of diabetic studies : RDS · on this map
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rodney RouseDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Leshuai ZhangDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Katherine SheaDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Hongfei ZhouDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Lin XuDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Sharron StewartDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Barry RosenzweigDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Jun ZhangDivision of Applied Regulatory Science, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Center for Drug Evaluation and Research · USUnited States Food and Drug Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study expanded upon a previous study in mice reporting a link between exenatide treatment and exocrine pancreatic injury by demonstrating temporal and dose responses and providing an initial mechanistic hypothesis. The design of the present study included varying lengths of exenatide exposure (3, 6 weeks to 12 weeks) at multiple concentrations (3, 10, or 30 µg/kg) with multiple endpoints (histopathology evaluations, immunoassay for cytokines, immunostaining of the pancreas, serum chemistries and measurement of trypsin, amylase, and, lipase, and gene expression profiles). Time- and dose-dependent exocrine pancreatic injury was observed in mice on a high fat diet treated with exenatide. The morphological changes identified in the pancreas involved acinar cell injury and death (autophagy, apoptosis, necrosis, and atrophy), cell adaptations (hypertrophy and hyperplasia), and cell survival (proliferation/regeneration) accompanied by varying degrees of inflammatory response leading to secondary injury in pancreatic blood vessels, ducts, and adipose tissues. Gene expression profiles indicated increased signaling for cell survival and altered lipid metabolism in exenatide treated mice. Immunohistochemistry supported gene expression findings that exenatide caused and/or exacerbated pancreatic injury in a high fat diet environment potentially by further increasing high fat diet exacerbated lipid metabolism and resulting oxidative stress. Further investigation is required to confirm these findings and determine their relevance to human disease.

Indexed as

AmylasesAnimalsApoptosisAutophagyDietary CarbohydratesDiet, High-FatDrug Administration ScheduleExenatideExocrine Pancreatic InsufficiencyHumansHypoglycemic AgentsLipaseLipid MetabolismMaleMiceMice, Inbred C57BLAmylasesDietary CarbohydratesExenatideHypoglycemic AgentsLipasePeptidesTrypsinVenoms

Identifiers

PMID25291183
PMCPMC4188617
OpenAlexW1967786294

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.